Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, Even | en_US |
dc.contributor.author | Chen, Bing-Mae | en_US |
dc.contributor.author | Su, Yu-Cheng | en_US |
dc.contributor.author | Chang, Yuan-Chih | en_US |
dc.contributor.author | Cheng, Tian-Lu | en_US |
dc.contributor.author | Barenholz, Yechezekel | en_US |
dc.contributor.author | Roffler, Steve R. | en_US |
dc.date.accessioned | 2020-10-05T02:02:01Z | - |
dc.date.available | 2020-10-05T02:02:01Z | - |
dc.date.issued | 2020-07-28 | en_US |
dc.identifier.issn | 1936-0851 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1021/acsnano.9b07218 | en_US |
dc.identifier.uri | http://hdl.handle.net/11536/155437 | - |
dc.description.abstract | Anti-polyethylene glycol (PEG) antibodies are present in many healthy individuals as well as in patients receiving polyethylene glycol-functionalized drugs. Antibodies against PEG-coated nanocarriers can accelerate their clearance, but their impact on nanodrug properties including nanocarrier integrity is unclear. Here, we show that anti-PEG IgG and IgM antibodies bind to PEG molecules on the surface of PEG-coated liposomal doxorubicin (Doxil, Doxisome, LC-101, and Lipo-Dox), resulting in complement activation, formation of the membrane attack complex (C51/-9) in the liposomal membrane, and rapid release of encapsulated doxorubicin from the liposomes. Drug release depended on both classical and alternative pathways of complement activation. Doxorubicin release of up to 40% was also observed in rats treated with anti-PEG IgG and PEG-coated liposomal doxorubicin. Our results demonstrate that anti-PEG antibodies can disrupt the membrane integrity of PEG-coated liposomal doxorubicin through activation of complement, which may alter therapeutic efficacy and safety in patients with high levels of pre-existing antibodies against PEG. | en_US |
dc.language.iso | en_US | en_US |
dc.subject | anti-PEG antibody | en_US |
dc.subject | PEG-coated liposomal doxorubicin | en_US |
dc.subject | PEGylated liposomal doxorubicin | en_US |
dc.subject | complement | en_US |
dc.subject | membrane attack complex | en_US |
dc.subject | drug release | en_US |
dc.title | Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1021/acsnano.9b07218 | en_US |
dc.identifier.journal | ACS NANO | en_US |
dc.citation.volume | 14 | en_US |
dc.citation.issue | 7 | en_US |
dc.citation.spage | 7808 | en_US |
dc.citation.epage | 7822 | en_US |
dc.contributor.department | 生物科技學系 | zh_TW |
dc.contributor.department | Department of Biological Science and Technology | en_US |
dc.identifier.wosnumber | WOS:000557762800011 | en_US |
dc.citation.woscount | 2 | en_US |
Appears in Collections: | Articles |